DBV Technologies S.A. (EPA:DBV)
3.805
-0.150 (-3.79%)
At close: Jan 30, 2026
DBV Technologies Revenue
Revenue (ttm)
$4.69M
Revenue Growth
-56.04%
P/S Ratio
239.59
Revenue / Employee
$40.08K
Employees
117
Market Cap
1.12B EUR
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | - | - | - |
| Dec 31, 2018 | 16.71M | 2.42M | 16.90% |
| Dec 31, 2017 | 14.29M | 4.73M | 49.50% |
| Dec 31, 2016 | 9.56M | 2.86M | 42.76% |
| Dec 31, 2015 | 6.70M | 933.42K | 16.20% |
| Dec 31, 2014 | 5.76M | 500.37K | 9.51% |
| Dec 31, 2013 | 5.26M | 1.60M | 43.65% |
| Dec 31, 2012 | 3.66M | 1.24M | 51.01% |
| Dec 31, 2011 | 2.43M | 143.69K | 6.30% |
| Dec 31, 2010 | 2.28M | 734.19K | 47.44% |
| Dec 31, 2009 | 1.55M | 93.10K | 6.40% |
| Dec 31, 2008 | 1.45M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Valneva SE | 179.91M |
| Cellectis | 70.36M |
| Genfit | 45.13M |
| MedinCell | 32.44M |
| Inventiva | 16.97M |
| Adocia | 12.88M |
| Innate Pharma | 12.64M |
| Nanobiotix | 10.16M |
DBV Technologies News
- 15 days ago - DBV Technologies Announces €166.7 Million in Gross Proceeds Following the Full Exercise of the ABSA Warrants and BS Warrants Issued on its March 2025 Financing - GlobeNewsWire
- 20 days ago - Information Regarding the Total number of Voting Rights and Total Number of Shares of the Company as of December 31, 2025 - GlobeNewsWire
- 27 days ago - Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of December 31, 2025 - GlobeNewsWire
- 5 weeks ago - The Insider Report: A Tape Fitting for the Holiday - Benzinga
- 6 weeks ago - DBV Launches, Up As Much As 46%, On A New Approach To Peanut Allergy - Investor's Business Daily
- 6 weeks ago - DBVT: HC Wainwright Raises Price Target to $40, Maintains Buy Rating | DBVT Stock News - GuruFocus
- 6 weeks ago - Toro, DBV Technologies, Udemy, ABM Industries And Other Big Stocks Moving Higher On Wednesday - Benzinga
- 6 weeks ago - Peanut Allergy Patch For Kids? DBV Technologies Advances Toward FDA Filing - Benzinga